Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole

References

• IbrahimEHShermanGWardSFraserVJKollefMHThe influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU settingChest200011814615510893372
   PubMed Web of Science ®Google Scholar
• IreguiMWardSShermanGFraserVJKollefMHClinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumoniaChest200212226226812114368
   PubMed Web of Science ®Google Scholar
• EagyeKJKimALaohavaleesonSKutiJLNicolauDPSurgical site infections: does inadequate antibiotic therapy affect patient outcomes?Surg Infect (Larchmt)20091032333119622027
   PubMed Web of Science ®Google Scholar
• ItaniKMAkhrasKSStellhornROutcomes associated with initial versus later vancomycin use in patients with complicated skin and skin-structure infectionsPharmacoeconomics20092742143019586079
   PubMed Web of Science ®Google Scholar
• CosgroveSEQiYKayeKSThe impact of methicillin resistance in Staphyblococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital chargesInfect Control Hosp Epidemiol20052616617415756888
   PubMed Web of Science ®Google Scholar
• LodiseTPMcKinnonPSClinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremiaDiagn Microbiol Infect Dis20055211312215964499
   PubMed Web of Science ®Google Scholar
• FalagasMEBarefootLGriffithJRuthazarRSnydmanDRRisk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infectionsEur J Clin Microbiol Infect Dis199615913921
   Web of Science ®Google Scholar
• ZilberbergMDShorrAFMicekSTEpidemiology and outcomes of hospitalizations with complicated skin and skin-structure infections: implications of healthcare-associated infection risk factorsInfect Control Hosp Epidemiol2009301203121019848604
   PubMed Web of Science ®Google Scholar
• RuheJJSmithNBradsherRWMenonACommunity-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcomeClin Infect Dis20074477778417304447
   PubMed Web of Science ®Google Scholar
• Research C-CfDEaGuidance for Industry: Uncomplicated and Complicated Skin and Skin Structure Infections – Developing Antimicrobial Drugs for TreatmentAdministration USDoHaHSFaDRockville, MD1998
   Google Scholar
• NicholsRLOptimal treatment of complicated skin and skin structure infectionsJ Antimicrob Chemother199944Suppl A192310511393
   PubMed Web of Science ®Google Scholar
• LeeSYKutiJLNicolauDPAntimicrobial management of complicated skin and skin structure infections in the era of emerging resistanceSurg Infect (Larchmt)2005628329516201938
   PubMedGoogle Scholar
• DiNubileMJLipskyBAComplicated infections of skin and skin structures: when the infection is more than skin deepJ Antimicrob Chemother200453Suppl 2ii37ii5015150182
   PubMedGoogle Scholar
• LeeMCRiosAMAtenMFManagement and outcome of children with skin and soft tissue abscesses caused by community- acquired methicillin-resistant Staphylococcus aureusPediatr Infect Dis J20042312312714872177
   PubMed Web of Science ®Google Scholar
• LleraJLLevyRCTreatment of cutaneous abscess: a double-blind clinical studyAnn Emerg Med19851415193880635
   PubMed Web of Science ®Google Scholar
• FungHBChangJYKuczynskiSA practical guide to the treatment of complicated skin and soft tissue infectionsDrugs2003631459148012834364
   PubMed Web of Science ®Google Scholar
• MoetGJJonesRNBiedenbachDJStilwellMGFritscheTRContemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998–2004)Diagn Microbiol Infect Dis20075771317059876
   PubMed Web of Science ®Google Scholar
• KlevensRMEdwardsJRRichardsCLJrEstimating health care-associated infections and deaths in U.S. hospitals, 2002Public Health Rep200712216016617357358
   PubMed Web of Science ®Google Scholar
• VandeneschFNaimiTEnrightMCCommunity-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergenceEmerg Infect Dis2003997898412967497
   PubMed Web of Science ®Google Scholar
• KingMDHumphreyBJWangYFEmergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infectionsAnn Intern Med200614430931716520471
   PubMed Web of Science ®Google Scholar
• TillotsonGSDraghiDCSahmDFSusceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005–07: laboratory-based surveillance studyJ Antimicrob Chemother20086210911518397923
   PubMed Web of Science ®Google Scholar
• PallinDJEganDJPelletierAJIncreased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureusAnn Emerg Med20085129129818222564
   PubMed Web of Science ®Google Scholar
• McCaigLFMcDonaldLCMandalSJerniganDBStaphylococcus aureus-associated skin and soft tissue infections in ambulatory careEmerg Infect Dis2006121715172317283622
   PubMed Web of Science ®Google Scholar
• HershALChambersHFMaselliJHGonzalesRNational trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infectionsArch Int Med20081681585159118663172
   PubMed Web of Science ®Google Scholar
• GuptaKMacintyreAVanasseGDembryLMTrends in prescribing beta-lactam antibiotics for treatment of community-associated methicillin-resistant Staphylococcus aureus infectionsJ Clin Microbiol2007453930393417942648
   PubMed Web of Science ®Google Scholar
• GorwitzRJJerniganDBPowersJHJerniganJAPrevention CfDCaParticipantsStartegies for clinical management of MRSA in the community: summary of an expert’s mettings convened by the CDCAtlanta, GA2005
   Google Scholar
• PowellJPWenzelRPAntibiotic options for treating community-acquired MRSAExpert Rev Anti Infect Ther2008629930718588495
   PubMed Web of Science ®Google Scholar
• SaderHSJonesRNAntimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007–2008)Diagn Microbiol Infect Dis20096515816219748426
   PubMed Web of Science ®Google Scholar
• Prevention CfDCaStaphylococcus aureus resistant to vancomycin-United States, 2002MMWR Morb Mortal Wkly Rep20025156556712139181
   PubMedGoogle Scholar
• Prevention CfDCaVancomycin-resistant Staphylococcus aureus-Pennsylvania, 2002MMWR Morb Mortal Wkly Rep20025190212418544
   PubMedGoogle Scholar
• Prevention CfDCaVancomycin-resistant Staphylococcus aureus-New York, 2004MMWR Morb Mortal Wkly Rep20045332232315103297
   PubMedGoogle Scholar
• DSM Pharmaceuticals ISynercid I.V. Prescribing InformationGreenville, NC2003
   Google Scholar
• DrewRHPerfectJRSrinathLTreatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study GroupJ Antimicrob Chemother20004677578411062197
   PubMed Web of Science ®Google Scholar
• NicholsRLGrahamDRBarriereSLTreatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection GroupJ Antimicrob Chemother19994426327310473234
   PubMed Web of Science ®Google Scholar
• LingTKFungKSChengAFIn vitro activity and post-antibiotic effect of quinupristin/dalfopristin (Synercid)Chemotherapy20014724324911399860
   PubMed Web of Science ®Google Scholar
• AuckenthalerRCourvalinPFegerCRocheGIn vitro activity of quinupristin/dalfopristin in comparison with five antibiotics against worldwide clinical isolates of staphylococciClin Microbiol Infect2000660861211168064
   PubMed Web of Science ®Google Scholar
• FritscheTRKirbyJTJonesRNIn vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infectionsDiag Microbiol Infect Dis200449201209
   PubMed Web of Science ®Google Scholar
• PatersonDLClinical experience with recently approved antibioticsCurr Opin Pharmacol2006648649016904377
   PubMed Web of Science ®Google Scholar
• FarrellDJMendesRERossJEJonesRNLinezolid surveillance program results for 2008 (LEADER Program for 2008)Diag Microbio Infect Dis200965392403
   PubMed Web of Science ®Google Scholar
• BeekmannSEGilbertDNPolgreenPMToxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections Network surveyDiag Microbiol Infect Dis200862407410
   PubMed Web of Science ®Google Scholar
• ArbeitRDMakiDTallyFPCampanaroEEisensteinBIThe safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infectionsClin Infect Dis2004381673168115227611
   PubMed Web of Science ®Google Scholar
• OlesonFBJrBermanCLKirkpatrickJBOnce-daily dosing in dogs optimizes daptomycin safetyAntimicrob Agents Chemother2000442948295311036005
   PubMed Web of Science ®Google Scholar
• PetersenPJJacobusNVWeissWJSumPETestaRTIn vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936)Antimicrob Agents Chemother19994373874410103174
   PubMed Web of Science ®Google Scholar
• DowzickyMJParkCHUpdate on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007Clin Ther2008302040205019108792
   PubMed Web of Science ®Google Scholar
• PapaparaskevasJTzouvelekisLSTsakrisAPittarasTELegakisNJIn vitro activity of tigecycline against 2423 clinical isolates and comparison of the available interpretation breakpointsDiagn Microbiol Infect Dis20106618719419836184
   PubMed Web of Science ®Google Scholar
• Ellis-GrosseEJBabinchakTDartoisNRoseGLohEThe efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonamClin Infect Dis200541Suppl 5S341S35316080072
   PubMed Web of Science ®Google Scholar
• RodvoldKAGotfriedMHCwikMSerum, tissue and body fluid concentrations of tigecycline after a single 100 mg doseJ Antimicrob Chemother2006581221122917012300
   PubMed Web of Science ®Google Scholar
• TombsNTissue distribution of GAR-936 a broad-spectrum antibiotic, in male ratsInterscience Conference on Antimicrobial Agents and ChemotherapySan Francisco1999
   Google Scholar
• Wyeth Pharmaceuticals ITygacil Prescribing InformationPhiladelphia2009
   Google Scholar
• StevensDLBisnoALChambersHFPractice guidelines for the diagnosis and management of skin and soft-tissue infectionsClin Infect Dis2005411373140616231249
   PubMed Web of Science ®Google Scholar
• NathwaniDNew antibiotics for the management of complicated skin and soft tissue infections: are they any better?Int J Antimicrob Agents200934Suppl 1S24S2919560672
   PubMed Web of Science ®Google Scholar
• Janssen-OrthoIZeftera Prescribing Information2008Toronto, OntarioJanssen-Ortho Inc2008
   Google Scholar
• MurthyBSchmitt-HoffmannAPharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activityClin Pharmacokinet200847213318076216
   PubMed Web of Science ®Google Scholar
• BarbourASchmidtSSabarinathSNSoft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysisAntimicrob Agents Chemother2009532773277619364847
   PubMed Web of Science ®Google Scholar
• Schmitt-HoffmannARoosBSchleimerMSingle-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteersAntimicrob Agents Chemother2004482570257515215110
   PubMed Web of Science ®Google Scholar
• BarbourASchmidtSRandKHDerendorfHCeftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA)Int J Antimicrob Agents2009341719261449
   PubMed Web of Science ®Google Scholar
• MurthyBSDWexlerDBalisDChangIDesai-KreigerDNoelGPharmacokinetics of ceftobiprole following single and multiple intravenous infusions administered to healthy subjects17th European Congress of Clinical Microbiology and Infectious Diseases MunichGermany2007
   Google Scholar
• Schmitt-HoffmannAHMHeepMBAL5788 in patients with complicated skin and skin structure infections caused by Gram-positive pathogens including methicillin-resistant Staphylococcus species (MRSS). 14th European Congress of Clinical Microbiology and Infectious DiseasesPrague2004
   Google Scholar
• MoutonJWSchmitt-HoffmannAShapiroSNashedNPuntNCUse of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141Antimicrob Agents Chemother2004481713171815105125
   PubMed Web of Science ®Google Scholar
• LodiseTPJrPypstraRKahnJBProbability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjectsAntimicrob Agents Chemother2007512378238717387149
   PubMed Web of Science ®Google Scholar
• KimkoHMurthyBXuXPopulation pharmacokinetic analysis of ceftobiprole for treatment of complicated skin and skin structure infectionsAntimicrob Agents Chemother2009531228123019075059
   PubMed Web of Science ®Google Scholar
• RodvoldKANicolauDPLodiseTPIdentifying exposure targets for treatment of staphylococcal pneumonia with ceftobiproleAntimicrob Agents Chemother2009533294330119451287
   PubMed Web of Science ®Google Scholar
• NoelGJBushKBagchiPIanusJStraussRSA randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infectionsClin Infect Dis20084664765518225981
   PubMed Web of Science ®Google Scholar
• NoelGJStraussRSAmslerKResults of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteriaAntimicrob Agents Chemother200852374417954698
   PubMed Web of Science ®Google Scholar
• ChewTASmithJMDetection of diacetyl (caramel odor) in presumptive identification of the “Streptococcus milleri” groupJ Clin Microbiol199230302830291452678
   PubMed Web of Science ®Google Scholar
• Schmitt-HoffmannANymanLRoosBMultiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteersAntimicrob Agents Chemother2004482576258015215111
   PubMed Web of Science ®Google Scholar
• FritscheTRSaderHSJonesRNAntimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005–2006)Diagn Microbiol Infect Dis200861869518385000
   PubMed Web of Science ®Google Scholar
• AmslerKMDaviesTAShangWJacobsMRBushKIn vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infectionsAntimicrob Agents Chemother2008523418342318591277
   PubMed Web of Science ®Google Scholar
• DaviesTAPageMGShangWBinding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniaeAntimicrob Agents Chemother2007512621262417470659
   PubMed Web of Science ®Google Scholar
• HebeisenPHeinze-KraussIAngehrnPIn vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococciAntimicrob Agents Chemother20014582583611181368
   PubMed Web of Science ®Google Scholar
• DeshpandeLMJonesRNBactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococciClin Microbiol Infect200391120112414616730
   PubMed Web of Science ®Google Scholar
• DeshpandeLRhombergPRFritscheTRSaderHSJonesRNBactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolatesDiag Microbiol Infect Dis2004507375
   PubMed Web of Science ®Google Scholar
• FritscheTRSaderHSJonesRNPotency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999–2004)Diagn Microbiol Infect Dis200758192617383139
   PubMed Web of Science ®Google Scholar
• QueenanAMShangWKaniaMPageMGBushKInteractions of ceftobiprole with beta-lactamases from molecular classes A to DAntimicrob Agents Chemother2007513089309517591851
   PubMed Web of Science ®Google Scholar
• PankuchGAAppelbaumPCPostantibiotic effect of ceftobiprole against 12 Gram-positive organismsAntimicrob Agents Chemother2006503956395817065631
   PubMed Web of Science ®Google Scholar
• AndesDWCIn-vivo pharmcodynamics of RO 63-9141 against multiple bacterial pathogens 40th Interscience Conference on Antimicrobial Agents and ChemotherapyToronto2000
   Google Scholar
• BogdanovichTEdnieLMShapiroSAppelbaumPCAntistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporinAntimicrob Agents Chemother2005494210421916189100
   PubMed Web of Science ®Google Scholar
• BogdanovichTClarkCEdnieLActivities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalisAntimicrob Agents Chemother2006502050205716723565
   PubMed Web of Science ®Google Scholar
• BanerjeeRGretesMBasuinoLStrynadkaNChambersHFIn vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureusAntimicrob Agents Chemother2008522089209618378703
   PubMed Web of Science ®Google Scholar
• ChambersHFEvaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureusAntimicrob Agents Chemother20054988488815728879
   PubMed Web of Science ®Google Scholar
• Azoulay-DupuisEBedosJPMohlerJEfficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumoniaAntimicrob Agents Chemother2004481105111115047508
   PubMed Web of Science ®Google Scholar
• CraigWAAndesDRIn vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection modelsAntimicrob Agents Chemother2008523492349618676887
   PubMed Web of Science ®Google Scholar
• FernandezJHilliardJJAbbanatDIn vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosaAntimicrob Agents Chemother20105411612519884364
   PubMed Web of Science ®Google Scholar
• AriasCASinghKVPanessoDMurrayBEEvaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis modelJ Antimicrob Chemother20076059459817606481
   PubMed Web of Science ®Google Scholar
• CraigWAPharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and menClin Infect Dis199826110 quiz 11–129455502
   PubMed Web of Science ®Google Scholar
• BurgessDSFreiCRComparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamicsJ Antimicrob Chemother20055689389816162664
   PubMed Web of Science ®Google Scholar
• BhavnaniSMWHICH PK-PD MEASURE FOR WHICH DRUG?International Society of Anti-Infective Pharmacology: WA Craig SymposiumMadison, WI, USA2008
   Google Scholar
• KimkoHXuXNandyPPharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infectionsAntimicrob Agents Chemother2009533371337419528285
   PubMed Web of Science ®Google Scholar
• LodiseTPJPypstraRKahnJBProbability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjectsAntimicrob Agents Chemother2007512378238717387149
   PubMed Web of Science ®Google Scholar